Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) Other Operating Expenses (2018 - 2021)

Historic Other Operating Expenses for AtriCure (ATRC) over the last 5 years, with Q3 2021 value amounting to -$107.6 million.

  • AtriCure's Other Operating Expenses fell 5614166.67% to -$107.6 million in Q3 2021 from the same period last year, while for Jun 2022 it was -$107.6 million, marking a year-over-year decrease of 239473.24%. This contributed to the annual value of -$102.5 million for FY2021, which is 2861148.46% down from last year.
  • As of Q3 2021, AtriCure's Other Operating Expenses stood at -$107.6 million, which was down 5614166.67% from $4.5 million recorded in Q4 2020.
  • In the past 5 years, AtriCure's Other Operating Expenses registered a high of $4.5 million during Q4 2020, and its lowest value of -$107.6 million during Q3 2021.
  • In the last 4 years, AtriCure's Other Operating Expenses had a median value of -$10.7 million in 2018 and averaged -$25.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 13243.89% in 2020, then tumbled by 5614166.67% in 2021.
  • AtriCure's Other Operating Expenses (Quarter) stood at -$10.7 million in 2018, then fell by 29.34% to -$13.9 million in 2019, then surged by 132.44% to $4.5 million in 2020, then plummeted by 2492.71% to -$107.6 million in 2021.
  • Its Other Operating Expenses stands at -$107.6 million for Q3 2021, versus $4.5 million for Q4 2020 and $192000.0 for Q3 2020.